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Danggui Buxue Tang (DBT),a Chineseherbal decoction used to treat ailments in women,containsRadix Astragali(Huangqi; RA)
and Radix Angelicae Sinensis (Danggui; RAS). When DBT was applied onto cultured MG-63 cells, an increase of cell proliferation
and diﬀerentiation of MG-63 cell were revealed: both of these eﬀects were signiﬁcantly higher in DBT than RA or RAS extract. To
search for the biological markers that are speciﬁcally regulated by DBT, DNA microarray was used to reveal the gene expression
proﬁling of DBT in MG-63 cells as compared to that of RA- or RAS-treated cells. Amongst 883 DBT-regulated genes, 403 of
them are speciﬁcally regulated by DBT treatment, including CCL-2, CCL-7, CCL-8, and galectin-9. The signaling cascade of this
DBT-regulated gene expression was also elucidated in cultured MG-63 cells. The current results reveal the potential usage of this
herbal decoction in treating osteoporosis and suggest the uniqueness of Chinese herbal decoction that requires a well-deﬁned
formulation. The DBT-regulated genes in the culture could serve as biological responsive markers for quality assurance of the
herbal preparation.
1.Introduction
Estrogen deﬁciency is the major cause in developing post-
menopausal osteoporosis. Estrogen acts on both osteoblast
and osteoclast to inhibit bone breakdown at all stages
of life. After menopause, estrogen replacement therapy is
an eﬀective treatment for osteoporosis as well as to allay
other menopausal symptoms [1]. However, estrogen therapy
recently became a subject of debate because clinical studies
revealed an increased risk of breast cancer and coronary
artery disease in women who take estrogen [2]. In view of
these clinical risks, extensive eﬀorts have been devoted to
develop diﬀerent strategies that would yield the beneﬁts of
estrogen therapy but with minimal side eﬀects [3]. Herbal
medicines, in particular the traditional Chinese medicine,
are promising preparations that have fewer side eﬀects[4, 5],
and which, indeed, have been used widely for menopausal
women as dietary supplements in Asia [6, 7].
Amongst thousands of herbal formulae from traditional
Chinese medicine, Danggui Buxue Tang (DBT; a herbal
decoction) is a simple combination of two herbs. DBT was
ﬁrst described in Neiwaishang Bianhuo Lun by Li Dongyuan
in China in AD 1247. Li described the DBT formula should
include: 10 qian of Radix Astragali (Huangqi; RA), roots of
Astragalus membranaceus(Fisch.)BungeorA.membranaceus
(Fisch.) Bunge var. mongholicus ( B u n g e )P . K .H s i a o ,a n dt w o
qian of Radix Angelicae Sinensis (Danggui; RAS), roots of
Angelica sinensis (Oliv.) Diels. One qian equals to about 3g.
In preparing DBT, the mixed herbs were recommended to
boilintwobowls ofwateroveramoderateheatuntiltheﬁnal2 Evidence-Based Complementary and Alternative Medicine
volume was reduced by half [8]. Traditionally, DBT has been
prescribed to women in China as a remedy for menopausal
symptoms. According to Chinese medicinal theory, the daily
intake of DBT could raise the “Qi” and nourish the “Blood”
of menopausal women.
Pharmacological results indicated that DBT has the abil-
ities to promote hematopoietic functions: to stimulate car-
diovascular circulation; to prevent osteoporosis; to increase
anti-oxidation activity, to stimulate immune response and
to mimic estrogen eﬀects in the receptor phosphorylation
[8, 9]. Besides, RA and RAS are commonly used in treating
the age-related diseases, which have been demonstrated in
stimulating bone cell proliferation, increasing bone forma-
tion and reducing bone re-sorption in patients [10]. By
determining the chemical and biological properties of DBT,
the optimized conditions of extraction have been established
[8, 9], which, interestingly, are in accordance with the weight
ratio of 5:1 for RA to RAS in the ancient preparation.
However, the rationale and action mechanisms for including
diﬀerent herbs in Chinese herbal decoctions had never been
fully explained, and more important biological markers
are missing in controlling the herbal decoction, which
consequently hinders the development of Chinese medicine
as disease and disorder remedies. In order to reveal the
speciﬁc events mediated by DBT in preventing osteoporosis,
cell proliferation and diﬀerentiation were determined in
culturedMG-63cells(anosteosarcomacellline).Inaddition,
DNA microarray analysis was used to analyze the gene
proﬁling in MG-63 cells after the treatments of extracts
derived from DBT, RA, or RAS. The identiﬁed DBT-speciﬁc
regulated genes in the cell culture could serve as biological
responsive markers in quality assurance of DBT and in
revealing the action mechanism of this decoction.
2.Methods
2.1. Plant Materials and Preparation of DBT. Fresh roots
were obtained from China in September to October of 2002:
3-year-old A. membranaceus var. mongholicus from Shanxi
and 2-year-old A. sinensis from Minxian of Gansu [11, 12]
Their corresponding vouchers as forms of whole plants,
voucher specimens for A. membranaceus var. mongholicus
and A.sinensis, were deposited in theDepartment ofBiology,
The Hong Kong University of Science and Technology,
China.InpreparingDBT,exactamountsofRASandRAwere
weighed according to a ratio of 5:1 and then mixed well by
vortex. The mixture was boiled in 8 volume of water (v/w)
for 2h, and extracted twice; this extraction was shown to
be the best extracting condition [8]. RAS or RA alone was
extracted by the same method. The extracts were dried by
lyophilization and stored at −80◦C.
2.2. Chemical Standarization of DBT. Ferulic acid was pur-
chased from Sigma (St Louis, MO), calycosin, formononetin
and ligustilide (z-isoform) were kindly provided by Prof.
Pengfei Tu, Medical College of Peking University; their
purities, conﬁrmed by HPLC, were >99.0%. AR and HPLC
grade reagents were from Merck (Darmstadt, Germany).
The HPLC system consisted of Waters (Milford, MA) 600
pump, 717 auto-sampler and UV/VIS Photodiode Array
2996 Detector were used for all analysis. Chromatographic
separations were carried out on a DELTA-PAK C18 column
(particle size 4.6μm, 3.9 × 150mm) with acetonitrile (as
Solvent A): 0.01% phosphoric acid (as Solvent B) as mobile
phase at a ﬂow rate of 1.0mL min−1 at room temperature.
A linear gradient elution was applied from 15 to 65% of
Solvent A starting from 0 to 60 min. Samples were ﬁltered
through a 0.45μm Millipore syringe ﬁlter unit. A sample of
20mL was injected for HPLC analysis. The calibration of
these chemicals followed previous reports [8, 9].
2.3. The Cultures of MG-63 Cells and Rat Osteoblasts.
Human osteosarcoma cell lineMG-63 was obtained from the
American Type Culture Collection (ATCC, Manassas, VA)
and was grown in Modiﬁed Eagle’s medium (MEM), sup-
plemented with 10% fetal bovine serum, 2mM l-glutamine,
0.1mM non-essential amino acids, 1mM sodium pyruvate,
100U mL−1 penicillin, and 100μgm L −1 streptomycin in a
humidiﬁed CO2 (5%) incubator at 37◦C. Culture reagents
were from Invitrogen (Carlsbad, CA, USA). Before 3 days
of the treatment, the medium was changed to MEM-α
without phenol red containing 2% charcoal-dextran-treated
fetal bovine serum. MG-63 cells were seeded onto 12-
well plate or 96-well plate in MEM-α medium. Next day,
the medium was replaced by fresh medium containing
1mgmL −1 DBT, RAS or RA extracts for 48h. 17β-Estradiol
(Sigma) dissolved in dimethyl sulfoxide (DMSO) was used
as a control. For the control vehicle, 0.0001% DMSO was
used. The cell number was determined by a manual cell
counting method. In brief, the drug-treated MG-63 cells
were detached by treatment with trypsin digestion and
resuspended in PBS, and the cell number was counted
by a hemocytometer. Besides, a biochemical colorimetric
method named 3-(4,5-dimethylthioazol-2-yl)-2,5-diphenyl-
tetrazolium bromide(MTT;Sigma)assay was employed.The
absorbance at 570nm was measured using an enzyme-linked
immunosorbent assay plate reader (Dynatech MR 5000)
[13]. A standard curve of cell number against absorbance
at 570nm was performed. All calibration was done within
the linear range of the standard curve. The enzymatic
activity ofalkaline phosphatasein MG-63cells was measured
by the hydrolysis of p-nitrophenyl phosphate as described
previously [14]. Brieﬂy, 100μL of the homogenate derived
fromthedrug-treatedMG-63cellswasaddedtothesubstrate
solution, which contained 10mM p-nitrophenyl phosphate
as a substrate in 100mM diethanolamine buﬀer (pH 10.5)
supplemented with 0.5mM MgCl2.A f t e r3 0m i no fi n c u b a -
tion at 37◦C, the reaction was terminated by addition of 2M
NaOH, and the activity was determined spectrophotometri-
cally (410nm) by measuring p-nitrophenyl released from the
substrate. The enzyme activity was expressed as micromole
of substrate cleaved per milligram of cell protein. For the
analyses of inhibitors, the cultures were pre-treated with
estrogen receptor antagonist ICI 182 780 (0.1μM; Tocris,
Ellisville, MO, USA) and Erk1/2 inhibitor U0126 (10μM;
Sigma) for 3h before the applicationof other drugs. Phorbol
12-myristate 13-acetate (0.1μM; TPA; Sigma) was used as an
Erk1/2 activator.Evidence-Based Complementary and Alternative Medicine 3
Primary culture of osteoblasts was performed according
to Orriss et al. [15]. In brief, calvarias from postnatal 5-day-
old rats were collected and undergone sequential enzymatic
digestion: 1% trypsin for 20min, 0.2% collagenase for
20min and 0.2% collagenase for 40min at 37◦C. After
centrifugation at 800g for 10min, supernatant containing
osteoblastic cells were collected and maintained in DMEM
with 10% FBS, 2mM l-glutamine, 0.1mM non-essential
amino acids, 1mM sodium pyruvate, 100U mL−1 penicillin,
and 100μgm L −1 streptomycin in a humidiﬁed CO2 (5%)
incubator at 37◦C. Cell viability was performed by MTT
assay as described before. Osteogenic diﬀerentiation was
induced by the treatment of vitamin C (250M) and dexam-
ethasone(20nM),orbytheherbalextracts, for 96hand then
subjected to total RNA extraction or alkaline phosphatase
assay.
2.4. DNA Microarray Analysis. MG-63 cultures were treated
1mgmL −1 RA,RASorDBTfor24htoextractthetotalRNAs
byTRIzolreagent(Invitrogen).RNAintegritywasconﬁrmed
by running the formaldehyde-denaturing gel, with purify of
ratio A260/280 > 1.8. Total RNAs were subjected to DNA
microarray analysis (Chipscreen Biosciences Ltd., Shenzhen,
China) to determine the diﬀerential gene expressions in
treated MG-63 cells. In brief, cDNAs from control and treat-
ment groups were labeled with Cy5 and Cy3 ﬂuorophores,
and hybridized with a DNA microarray chip containing
7458 candidate genes and 384 reference genes. Signals were
captured by Generation III array scanner (GE Healthcare,
Piscataway, NJ, USA) and data were analyzed by Imagequant
5.0 and Array Vision 6. The signiﬁcant changes of gene
expressions were deﬁned as up-regulation when ﬂuorescent
signal in sample was greater than that of control for 200%,
or down-regulation when the signal was less than that for
50%.
2.5. Estrogen-Activated Promoter Assay. Three repeats of
estrogen responsive elements (ERE: 5 -GGT CAC AGT
GAC C-3 ) was synthesized as described previously [9, 16],
and then subcloned into a promoter-reporter vector called
pTAL-Luc (Clontech, Mountain View, CA, USA) that has
a down stream reporter of ﬁreﬂy luciferase gene; this DNA
construct was named as pERE-Luc. Cultured MG-63 cells
were transfected with pERE-Luc to generate the stable cell
line according to a previous report [17]. Serving as controls,
tworeporterscontainingthreerepeatsofresponsiveelements
for myocyte enhancing factor 2 (MEF2; 5 -CTA AAA ATA
G-3  in forming pMEF2-Luc) and muscle-regulated tran-
scription factors (MRF; 5 -CAG TTG-3  in forming pE-box-
Luc) were constructed in pTA-Luc. Both MEF2 and E-box
are muscle-speciﬁc gene activation elements. To determine
the estrogenic property, diﬀerent concentration of estrogen,
DBT or other extract were applied onto the cultures for
48h. Afterward, the medium was aspirated, and MG-63
cells were washed by cold PBS. The cells were lysed by a
buﬀer containing 0.2% Triton X-100, 1mM dithiothreitol
and 100mM potassium phosphate buﬀer (pH 7.8) at 4◦C.
Followed by centrifugation at 14000rpm for 4◦C1 0m i n ,
supernatant was collected and used to perform luciferase
assay (Tropix Inc., Bedford, MA, USA); the activity was
normalized by equal amount of protein.
2.6. Determination of Phosphorylation. The phosphoryla-
tion of extracellular signal-regulated kinases (Erk)1/2 was
determined by western blot assay. The cultures were serum
starved with or without the inhibitors for 3h before
the drug applications. After drug treatments, the cultures
were collected immediately in lysis buﬀer (125mM Tris-
HCl, 2% SDS, 10% glycerol, 200mM 2-mercaptoethanol,
pH 6.8), and the proteins were subjected to SDS-PAGE
analysis. Phosphorylated Erk1/2 were recognized by anti-
phospho-Erk1/2 antibody (1:5000; Cell Signaling, Danvers,
MA, USA) at 4◦C for 12h, and horseradish peroxidase
(HRP)-conjugated anti-rabbit secondary antibody (1:5000;
Invitrogen) for 1h at room temperature. The immuno-
complexes were visualized by the enhanced chemilumines-
cence (ECL) method (GE Healthcare). The band intensities,
recognized by the antibodies in the ECL ﬁlm, in control
a n da g o n i s t - s t i m u l a t e ds a m p l e sw e r er u no nt h es a m eg e l
and under strictly standardized ECL conditions. The bands
were compared on an image analyzer, using in each case a
calibration plot constructed from a parallel gel with serial
dilution of one of those samples: this was to ensure the sub-
saturation of the gel exposure.
2.7. PCR Analysis. MG-63 cells, or primary cultures of rat
osteoblasts, with or without inhibitor pre-treatments were
treated with 1mg mL−1 DBT, RA or RAS extract for 12h.
T o t a lR N A sw e r ei s o l a t e db yT R I z o lr e a g e n t( I n v i t r o g e n ) ,
and 5μg of total RNA was reverse-transcribed by Moloney
Murine Leukemia Virus Reverse Transcriptase (Invitrogen)
according to the manufacturer’s instructions. Qualitative
PCR was performed to determine the expression of estrogen
receptor (ER) α and β. The primers were: 5 -TGA AGC ACA
AGC GTC AGA GA-3  and 5 -CGT AGC CAG CAA CAT
GTC AA-3  for ER α (501bp), 5 -CTC TTG GAG AGC TGT
TGG AT-3  and 5 -CTG TGA CCA GAG GGT ACA T-3 
for ER β (259bp), with conditions of 94◦C( 1 m i n ) ,6 0 ◦C
(1min) and 72◦C (1 min) for 30 cycles. The real-time PCR
was performed by using SYBR Green Master Mix and Rox
reference dye according to the manufacturer’s instructions
(Applied Bioscience, Foster city, CA, USA). The primers for
other transcripts were: 5 -TGT GAT GCC CTT AGA TGT
CC-3  and 5 -GAT AGT CAA GTT CGA CCG TC-3  for 18S
rRNA (320bp), 5 - T T CA T CA C CA C CA T TC T GG G - 3  
and 5 -CAT GGG TCA GCT GGA TGT C-3  for galectin-9
(289bp); 5 -AAG GAG GTC TGT GCT GAC-3  (common
c h e m o k i n eC - Cm o t i f ;C C Ls e n s ep r i m e r )a n d5  -GAT TCT
TGC AAA GAC CCT-3 ,o r5  -AGA GAA GGG AGG AGC
AT-3  or 5 -AGG ATG TAT GAC AGA TAG AG-3  for CCL-
2 (242bp), CCL-7 (356bp) or CCL-8 (364bp), respectively.
SYBR green signal was detected by Mx3000ptm multiplex
quantitative PCR machine (Stratagene, La Jolla, CA, USA),
with annealing temperature at 60◦C in all cases. Transcript
levels were quantiﬁed by using the ΔΔCt value method [18].
Calculation was done by using the Ct value of 18S rRNA
to normalize the Ct value of target gene in each sample
to obtain the ΔCt value, which then was used to compare4 Evidence-Based Complementary and Alternative Medicine
among diﬀerent samples. PCR products were analyzed by gel
electrophoresisandmeltingcurveanalysistoconﬁrmspeciﬁc
ampliﬁcations.
2.8. Other Assays. The protein concentrations were mea-
sured routinely by Bradford’s method with a kit from
Bio-Rad Laboratories (Hercules, CA, USA). Statistical tests
were made by the Primer program, version 1 (Primer of
Biostatistics): diﬀerences from basal or control values (as
shown in the plots) were classed as signiﬁcant (∗)w h e r eP
< .05, (∗∗)w h e r eP < .01 and highly signiﬁcant (∗∗∗)w h e r e
P < .001 by Student’st test.
3.Results
3.1. The Osteogenic Properties of DBT in Cultured MG-
63 Cells. DBT, composed of RA and RAS in a weight
ratio of 5:1, was prepared according to the optimized
extraction conditions as described previously [8]. In order
to standardize the herbal extract chemically, we generated
HPLC ﬁngerprints: these ﬁngerprints were required as to
ensure the chemical composition of DBT, or extracts from
RA and RAS, in all pharmacological experiments (Figure 1).
By discovering the amounts of two chemical markers in RA
(calycosinand formononetin) andtwo othersinRAS(ferulic
acid and ligustilide), we were able to standardize the optimal
DBT. We found that the standardized DBT should contain
0.186mgcalycosin,0.155mgformononetin, 0.351mgferulic
acid and 0.204mg ligustilide per 1g dried weight of DBT;
this was in line to our previous studies [8, 9]. In addition,
a standardized extract of RA in 1g should contain 0.088mg
calycosin and 0.142mg formononetin, while the extract of
RAS in 1g should have 0.293mg ferulic acid and 0.316mg
ligustilide. From the calculations of extraction eﬃciency, the
yield of DBT, RA and RAS were in a range from 29 to 32%±
3% (n = 5).
Amongst diﬀerent eﬀects of DBT in cell cultures, we
decided to used cultured bone cells as the study model
here;becauseDBT-inducedbonecelldiﬀerentiationhasbeen
described [8]. MG-63 cell, a human cell line that exhibits
phenotypic properties of osteoblast is a common cell line
used in analyzing bone formation [19]. More importantly,
the comparison between MG-63 cells and primary culture
of osteoblasts had been done, which showed that the two
types of osteoblastic cells shared a close similarity in terms
of synthesis and display of glycan structures [20].
By using cell counting and MTT assay, the proliferation
of MG-63 cells induced by DBT, RA, RAS, RA + RAS
(boiled separately and then mixed together in 5:1 ratio)
and estrogen were determined. As shown in Figure 2(a),
DBT increased the cell number (from cell counting) and the
proliferation (from MTT assay) of MG-63 cells by ∼42%
and ∼18%, respectively, as compared with the control. This
induction eﬀect of cell proliferation was signiﬁcantly higher
than the eﬀe c t so fR A ,R A S ,o rR A+R A S .T h ep o s i t i v e
control, 17β-estradiol at 10 and 100 nM, caused a marked
increase in the cell proliferation. The vehicle did not aﬀect
the proliferation status of MG-63 cells.
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Figure 1: Chemical standardization of DBT by HPLC ﬁngerprint
analysis. In the HPLC ﬁngerprint at an absorbance of 254nm,
the peaks corresponding to ferulic acid, calycosin, formononetin,
and ligustilide in DBT, RA, and RAS are indicated by arrowheads.
The details of the marker identiﬁcation were described previously
[8]. These chemical characterizations are used to identify the
standardized extracts for all the biochemical analyses. Typical
ﬁngerprints are shown.
The increase of alkaline phosphatase activity in MG-
63 cells occurs at the middle stage of diﬀerentiation, which
could serve as an indicator of osteoblastic diﬀerentiation
[21].Similartotheeﬀectofcellproliferation,DBTinduced∼
22% increase in alkaline phosphatase activity; this induction
was signiﬁcantly higher than that of RA, RAS or RA + RAS
(Figure 2(b)).17β-Estradiol at10and100nMcaused ∼6and
28% increase in the enzyme activity. In the DBT-induced
cell proliferation and diﬀerentiation, the eﬀects of DBT
in cultured MG-63 cells were revealed in dose-dependent
manners (Figure 2(c)). Both of the assays were rather similar
that 0.1mg mL−1 of DBT showed an induction eﬀect at
∼50%.
3.2. Genomic Analysis of DBT-Treated Cells. In a Chinese
herbal decoction, we are dealing with multi-components
and multi-targets of the pharmacological eﬀects. Lacking
a speciﬁc biological marker and detail analysis of action
mechanism are major obstacle to increase the usage of
Chinese medicine. Thus, genomic approach was used here
to reveal the gene expression proﬁling in DBT-treated MG-
63 cells. The osteoblastic cell line was used here for genomic
analysis instead of primary cultured osteoblasts: this was to
ensure the consistence of DNA microarray results. The DNA
microarray result was summarized in the supplementary
table posted in the supplementary information. Figure 3(a)
shows a summary of the genomic result. In brief, there
are 883 genes are regulated by DBT treatment and 403
are DBT-speciﬁc; 660 genes are regulated by RA treatmentEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: DBT increases the cell proliferation and alkaline phosphatase activity in cultured MG-63 cells. (a) Cultured MG-63 cells were
treated with extracts (1mg mL−1) derived from DBT, RA, RAS, and RA + RAS for 48h to determine the cell proliferation by cell counting
(upper panel) and MTT assay (lower panel). β-Estradiol (E2; 10 and 100nM) was used as a positive control, while 0.0001% DMSO served
as a vehicle. (b) Cultures were treated as in (a) to determine the enzymatic activity ofalkalinephosphatase(ALP).(c) A dose-response curve
of DBT was performed for both assays as in (a) and (b), with treatment time for 48h. Values are expressed in percentage of increase as
compared with control cultures (without herbal extract), and are in mean ± SEM, where n = 5, each with triplicate samples. ∗∗P < .01.
and 172 are RA-speciﬁc; 1062 genes are regulated by RAS
treatment and 473 are RAS-speciﬁc. In addition, 279 genes
are commonly regulated by the extracts of DBT, RA, and
RAS. These numbers already provides us a snapshot that the
gene activation of DBT is in distinction to that of a simple
addition of RA + RAS extracts.
Amongst the 883 DBT-regulated genes, many of them
are known, directly or indirectly, to play roles in bone
formation (Table 1). The degree of regulation was varied
among diﬀerent analyzed genes; the highly regulated genes
were galectin-9, CCL-8, CCL-7, and CCL-2. Thus, they
were selected for validation by quantitative real-time PCR
analysis. As expected from the DNA microarray results, the
transcripts encoding CCL-2, CCL-7, CCL-8, and galectin-9
were markedly increased by DBT treatment (Figure 3(b)).
The transcript expressions of galectin-9, CCL-2, and CCL-8
were increased by 12- to 17-folds after the challenge of DBT,
while the expression level of CCL-7 mRNA was up regulated
with an induction over 50-fold. In line to the result of DNA
microarray analysis, the eﬀects of DBT were signiﬁcantly
higher than the extracts derived from RA, RAS or even the
simple mixture of RA and RAS, which suggested a strong
synergistic eﬀect in combination of RA and RAS and a
crucial role of boiling the two herbs together. By comparing
the results from the microarray analysis, the transcript
induction by the determination of real-time PCR revealed a
lower value, which could be accounted by the sensitivity of
two diﬀerent assays.6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: DNA microarray analysis of DBT-induced speciﬁc gene expressions and validation in cultured MG-63 cells. (a) MG-63 cells were
treated with 1mg mL−1 RA, RAS, or DBT for 24h and subjected to DNA microarray analysis to determine the diﬀerential gene expressions.
The DNA chip contained 7458 candidate genes and 384 reference genes: these sequences were derived from human genome. Signiﬁcant
changes of gene expressions were deﬁned as regulated, either up-regulation when ﬂuorescent signal in the sample was greater than that of
control for 200%, or down-regulation when the signal was less than that for 50%. (b) Some of up-regulated genes as in (a) was validated
by quantitative real-time PCR analysis.Total RNAs were extracted from cultures treated with diﬀerent extracts for 24h and used to perform
real-time PCR analysisto determine the mRNA levels of CCL-2, CCL-7, CCL-8, and galectin-9. Data are normalized by ΔΔCt method using
18S rRNA as an internal control, and expressed as the ratio to basal reading where control (without herbal extract) equals to 1, and in mean
± SEM, where n = 5, each with triplicate samples.
Table 1: Genes related to bone development are up regulated by DBT.
Regulated genea Symbol Genbank no. Fold of changeb
DBT RAS RA
Lectin, galactoside-binding, soluble, 9 (Galectin-9) LGALS9/Gal-9 AA434102 441.76 1.60 1.77
Small inducible cytokine subfamily A, member 8 SCYA8/CCL-8 AI268937 184.65 2.73 2.89
Small inducible cytokine A7 SCYA7/CCL-7 AA040170 175.02 0.33 6.96
Small inducible cytokine A2 SCYA2/CCL-2 AA425102 88.22 2.35 6.87
Collagen, type XVIII, α1C O L 1 8 α1 N81029 4.49 5.03 3.99
Matrix metalloproteinase 9 MMP9 T72581 3.87 5.78 7.15
Collagen, type X, α1C O L 1 0 α1 AI828306 3.44 4.09 13.95
Transforming growth factor, β2T G F β2 AA233738 2.60 3.40 1.77
Insulin-like growth factor 1 IGF1 AA456321 2.47 — —
Bone morphogenetic protein 1 BMP1 R56774 2.29 2.88 6.66
Epidermal growth factor EGF AI480081 2.00 1.19 —
Integrin, α2I T G α2 AA463257 1.87 0.75 0.85
Msh (Drosophila) homeo box homolog2 MSX2 AA195636 1.86 1.14 0.82
Collagen, type VII, α1C O L 7 α1 AA598507 1.86 3.49 1.76
Bone morphogenetic protein 6 BMP6 AA424833 1.73 2.28 1.27
Msh (Drosophila) homeo box homolog1 MSX1 AA464197 1.66 1.45 1.28
Fibroblast growth factor receptor 3 FGFR3 AA419620 1.65 0.97 0.82
Cartilage oligomericmatrix protein COMP N94385 1.64 1.30 4.82
Transforming growth factor, β1T G F β1 R36467 1.56 1.94 2.00
Bone morphogenetic protein 8 BMP8 AA779480 1.41 1.73 1.30
Bone morphogenetic protein 7 BMP7 W73473 1.39 1.75 1.64
Fibroblast growth factor receptor 1 FGFR1 R54846 1.36 1.17 1.25
Multiple inositol polyphosphate phosphatase1 MINPP1 AA161161 0.29 0.47 0.57
aGenes known to play role in bone development are selected for illustration; bChange of gene expressions as compared to the control (no drug treatment).
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Figure 4: DBT induces the estrogenic eﬀects in cultured MG-63 cells. (a) Three repeats of estrogen responsive elements (ERE: 5 -GGT
CAC AGT GAC C-3 ) was subcloned into a promoter-reporter vector that has a down stream reporter of ﬁreﬂy luciferase gene, namely as
pERE-Luc. (b) Cultured MG-63 cells that stably transfected with pERE-Luc, or transiently transfected with pMEF2-Luc or pE-box-Luc were
treated with diﬀerent concentration of β-estradiol (E2; from 10nM to 1μM) for 48h to determine the transcriptional activity of pERE-Luc
by luciferase assay. (c) Total RNAs were extracted from MG-63 cells to determine the presence of estrogen receptor α (ERα; 510 bp) and β
(ERβ; 259bp) by RT-PCR analysis. No RT indicated the absence of contamination by genomic DNA, and ERα and ERβ cDNAs served as
positive control for PCR. Representative images were shown, n = 5. (d) Cultures were treated with extracts (1mg mL−1) derived from DBT,
RA, RAS and RA + RAS for 48h to determine the luciferase activity as in (b). (e) A dose-response curve of DBT was performed as in (b).
Values of the promoter-driven luciferaseactivities are expressed in percentage of increase as compared with control cultures (without herbal
extract), and in mean ± SEM, where n = 5, each with triplicate samples. ∗∗P < .01.
3.3. Signaling Mechanisms of DBT-Speciﬁc Gene Regulation.
The signaling mechanism of this DBT-induced gene expres-
sion was revealed here. DBT has been shown to activate
two signaling cascades in diﬀerent cell types: (i) estrogenic
signal; and (ii) mitogen-activated protein (MAP) kinase
signal [9, 22]. In order to test the estrogenic eﬀects of
DBT in cultured MG-63 cells, a promoter-reporter construct
(pERE-Luc; see Figure 4(a)) containing three repeats of
estrogen-responsive element (ERE) was stably transfected
into MG-63 cells. Treatment of 17β-estradiol from 10nM8 Evidence-Based Complementary and Alternative Medicine
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Figure 5: DBT induces Erk1/2 phosphorylation in cultured MG-63 cells. MG-63 cultures were serum starved for 3h before the addition
o fD B T ,R A ,R A S ,a n dR A+R A Se x t r a c t s( 1m gm L −1)f o rd i ﬀerent time. Total and phosphorylated inhibitor Erk1/2 and P-Erk1/2 were
revealed by western blot analysis using speciﬁc antibodies. TPA at 0.1μM served as a control. The lower panel shows the quantitation of
phosphorylation from the blots by calibrating the densitometry. Values are expressed as the ratio to basal reading where time 0 equals to 1,
and in mean ± SEM, where n = 4.
to 1μM produced a dose-dependent response in activating
the activity of pERE-Luc in the stable transfected cell
(Figure 4(b)). In contrast, no estrogenic eﬀect was found in
either pMEF2-Luc or pE-box-Luc transfected MG-63 cells.
Such estrogen-mediated transcriptional activity was further
conﬁrmed by the presence of ERα and β mRNAs in cultured
MG-63cells(Figure 4(c)).Noreversetranscriptionindicated
the absence of contamination by the genomic DNA. The
cDNAs encoding ERα and ERβ served as positive controls
forPCR.These resultswere consistent with theliteraturethat
bothERα and β were present in MG-63 [23, 24]. Inaddition,
the expressions of ERα and β were not altered in our drug-
treated cultures.
To test the eﬀect of DBT, diﬀerent amounts of DBT
were applied onto the pERE-Luc-transfected MG-63 cells
for 2 days. Application of DBT led to the activation of
promoter activity by an increase of 230%: the potency was
the strongest among diﬀerent herbal extracts being tested
(Figure 4(d)). Application of 1mg mL−1 RA or 1mg mL−1
RA + RAS (boiled separately and then mixed together) also
induced promoter activity to ∼110%; however, the activity
was lower when compared with the activity of DBT. RAS
(1mg mL−1) did not have any activation eﬀect(Figure 4(d)).
Showing the speciﬁcity of DBT response, the muscle-speciﬁc
gene responsive elements, MEF2 and E-box, did not respond
to the challenge of DBT. In addition, the DBT treatment
showed a dose-dependent response in activating pERE-
driven luciferase activity (Figure 4(e)). This estrogenic eﬀect
of DBT has been shown previously in cultured MCF-7 cells
(a breast cancer cell line) and the potency is comparable [9],
whichindicatedthepossession ofestrogenicpropertyofDBT
in cultured MG-63 cells.
MAPkinases are involvedin numerous cellularresponses
includingcell growthand diﬀerentiation, and they have been
shown to participate in estrogenic eﬀects. Therefore, we
studied the phosphorylation of Erk1/2, a MAP kinase with
an important roleintheclassicalRaf-MEK-Erk pathway.The
serum-starved MG-63 cultures were treated with diﬀerent
drugs and collected at diﬀerent times. The phosphorylations
ofErk1 (P-Erk1; ∼44 kDa)and Erk2 (P-Erk2; ∼42kDa)were
markedly increased by the addition of DBT; the activation
was transient and peaked at over 10-fold in 5–10min
after the treatment (Figure 5). In comparison to DBT, the
phosphorylation of Erk1/2 was also increased by ∼7-fold
when MG-63 cells were treated with RA or RAS (Figure 5).
As a control, the application of TPA, a known activator ofEvidence-Based Complementary and Alternative Medicine 9
(a)
(b) (c)
∗∗∗ ∗∗∗
U
0
1
2
6
D
M
S
O
I
C
I
1
8
2
,
7
8
0
D
M
S
O 0
100
200
L
u
c
i
f
e
r
a
s
e
a
c
t
i
v
i
t
y
(
%
o
f
i
n
c
r
e
a
s
e
)
0
4
8
E
r
k
p
h
o
s
p
h
o
r
y
l
a
t
i
o
n
(
%
o
f
i
n
c
r
e
a
s
e
)
∗∗∗ ∗∗∗
∗∗
G
a
l
e
c
t
i
n
-
9
C
C
L
-
8
C
C
L
-
7
C
C
L
-
2
DMSO + DBT
ICI 182, 780 + DBT
U0126 + DBT
0
4
8
12
16
48
52
56
m
R
N
A
(
x
b
a
s
a
l
)
∗∗∗
0
20
40
C
e
l
l
n
u
m
b
e
r
(
%
o
f
i
n
c
r
e
a
s
e
)
∗∗∗
0
10
20
P
r
o
l
i
f
e
r
a
t
i
o
n
(
%
o
f
i
n
c
r
e
a
s
e
)
∗∗∗
0
10
20
A
L
P
a
c
t
i
v
i
t
y
(
%
o
f
i
n
c
r
e
a
s
e
)
U
0
1
2
6
D
M
S
O
I
C
I
1
8
2
,
7
8
0
Figure 6: The DBT-induced osteogeniceﬀects and gene expressions are blocked by speciﬁc inhibitors. (a) MG-63 cultures stably transfected
with pERE-Luc were pre-treated with buﬀer (0.1% DMSO;control), ICI 182 780 (an ER blocker; 0.1μM) and U0126 (Erk inhibitor; 10μM)
for 3h before the addition of DBT (1mg mL−1) for 24h to determine the luciferase activity driven by ERE activation (left panel) and
Erk1/2 phosphorylation at 5 min (right panel). (b) Cultures were treated for 48h as in (a) to determine cell number (by cell counting), cell
proliferation (by MTT assay) and alkaline phosphatase (ALP) activity. (c) To investigate the signaling mechanisms of DBT-induced gene
expressions, MG-63 cells were pre-treated with inhibitors and then DBT as in (a) for 24h to measure the change of CCL-2, CCL-7, CCL-
8, and galectin-9 mRNA expressions by real-time PCR analysis. Values are expressed in percentage of increase as compared with control
cultures (without herbal extract), and in the ratio to basal reading where control (without herbal extract) equals to 1, mean ± SEM, where n
= 5, each with triplicate samples. ∗∗P < .01, ∗∗∗P < .001.
Erk1/2, induced the phosphorylation of Erk1/2 by ∼10-fold
in a sustained manner.
To distinguish the role of estrogenic and MAP kinase
signalings on DBT-induced eﬀects in MG-63 cells, speciﬁc
inhibitors for ER and MAP kinase, ICI 182 780 and
U0126, respectively, were used to test the regulatory eﬀects
of DBT. The blocking eﬀects by these inhibitors were
shown in Figure 6(a). Cultures were pre-treated with
inhibitors, or DMSO (control), for 3h before the application
of DBT (1mg mL−1) for 2 days. The DBT-induced
pERE-Luc transcriptional activity was decreased by the
pre-treatment of ER blocker ICI 182 780. Besides, the DBT-
induced Erk1/2 phosphorylation was reduced by U0126
application (Figure 6(a)). In cultured osteoblastic cells, both
of the inhibitors partially blocked the DBT-induced cell
proliferation and alkaline phosphatase activity (Figure 6(b)).
These pharmacological studies suggested that the activation
eﬀects of DBT could be mediated, at least, by two signaling
pathways: ER-dependent and Erk-dependent, which could
be partially accounted for the regulatory mechanisms of10 Evidence-Based Complementary and Alternative Medicine
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Figure 7: DBT stimulates the osteogenic diﬀerentiation of cultured primary osteoblasts.(a) Primaryculture of osteoblasts were treated with
1mgmL −1 DBT, RA, RAS, RA + RAS, andDex + VitaminC (positive control). After 96-h incubation, cultures were collected to perform cell
proliferationand alkalinephosphatase activity assaysas in Figure 2. Values are expressed in percentage of increase as compared with control
cultures (withoutherbal extract), and are in mean ± SEM,where n = 5, each with triplicate samples. ∗∗P < .01. (b) Primary osteoblasts were
treated as in (a) for 12h. Total RNAs were collected to determine the change of CCL-2, CCL-7, CCL-8, and galectin-9 mRNA expressions
by real-time PCR analysis as in Figure 3. Data are normalized by ΔΔCt method using 18S rRNA as an internal control, and expressed as the
ratio to basal reading where the control (without herbal extract) equals to 1, and in mean ± SEM, where n = 5, each with triplicate samples.
DBT in triggering the proliferation and diﬀerentiation of
osteoblastic cells.
Moreover, the roles of these inhibitors in DBT-regulated
genes were also investigated by real-time PCR analysis.
Application of the two inhibitors blocked the DBT-induced
mRNA expressions in diﬀerent extent; the blockage of CCL-
8 was signiﬁcant with more than 75% (Figure 6(c)). For
galectin-9, the suppression eﬀect of U0126 was greater than
ICI 182 780. On the contrary, the DBT-induced CCL-2 and
CCL-7 genes were totally unaﬀected by the two inhibitors
(Figure 6(c)). These results suggest the diversity of the
DBT-induced downstream signaling in cultured osteoblasts,
that is, gene transcription is triggered via distinct signaling
cascades.
3.4. Osteogenic Eﬀects of DBT in Rat Osteoblasts. To further
support the beneﬁcial roles of DBT on bone development,
the primary culture of rat osteoblasts was employed here as
another study model. The osteoblastic cultures were treated
with diﬀerent extracts for 96 h and collected to perform cell
proliferation and alkaline phosphatase assays. As expected,
DBTincreasedthecellproliferationandalkalinephosphatase
activity by ∼20% (Figure 7(a)), while the eﬀects of RA, RAS
or RA + RAS were all <10%. Dexamethasone and vitamin
C (Dex + Vitamin C) served as a positive control for both
assays. In addition, the speciﬁc gene transcriptions in DBT-
treated cultures were determined. The results from real-time
PCR analysis indicated that the four target genes, CCL-2,
CCL-7,CCL-8,andgalectin-9,werestimulatedbyDBTforat
least 4-fold (Figure 7(b)). On the other hand, the change of
mRNA levels in RA-, RAS- or RA + RAS-treated osteoblasts
were <2-fold. These results were consistent with that of
MG-63 cells (Figures 2 and 3), which greatly supported the
uniqueness of DBT decoction and the beneﬁcial eﬀects of
DBT on the osteoblastic cells.
4.Discussion
This study, for the ﬁrst time, demonstrated the trophic roles
ofanancientChineseherbaldecoctionhavingacombination
of RA and RAS in a weight ratio of 5:1 on bone cells.
Based on our current results, a brief summary was proposed
(Figure 8). According to the ancient formulation, the DBT
decoction was prepared by boiling RAS and RA together in
1:5 mass ratio. Application of DBT onto osteoblastic cells
triggered the downstream signaling cascades including the
Erk-dependent and ER-dependent pathways. Such signaling
activations ﬁnally resulted in stimulating cell proliferation,
osteogenic diﬀerentiation and a set of DBT-regulated gene
transcription. DBT possesses a better eﬀect in stimulating
cell proliferation and diﬀerentiation in cultured MG-63 cells
and primary osteoblasts, as compared to that of the extracts
derived from RA or RASor RA + RAS(boiled separately and
then mixed together in 5:1 ratio). In line to this activation
eﬀect, genomic analysis revealed a speciﬁc set of genes being
regulated by DBT, but not by RA or RAS alone. These results
therefore provide evidence of the uniqueness of speciﬁc
combination of RA and RAS in creating the formulation
of DBT. In addition, the insuﬃcient stimulating eﬀect of
RA + RAS in cultured MG-63 cells suggests that boiling
of the two herbs together is essential; this method of DBT
preparation,indeed,haslongbeenrecommendedbyChineseEvidence-Based Complementary and Alternative Medicine 11
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Figure8:SummaryforDBT-inducedosteogeniceﬀectsandspeciﬁc
gene expressions in osteoblastic cells. Application of DBT onto
osteoblastic cells triggers the downstream signaling mechanisms
including the Erk-dependent and ER-dependent pathways, which
may be mediated directly by DBT or indirectly by a receptor(s)
on plasma membrane. Such signaling activations ﬁnally result in
stimulating cell proliferation, osteogenic diﬀerentiation, and a set
of speciﬁc gene transcriptions.
medicinal practitioners. Although the concentration of DBT
i nc e l lc u l t u r em a yn o tb er e l e v a n tt ot h a to ft h ee ﬀective
concentration in animal, the eﬀectsof DBTat mg mL−1 have
been shown to be highly signiﬁcant in diﬀerent cell types
[8, 9, 25]. In addition, the oral administration of DBT at
a concentration of g/kg could markedly aﬀect the oxidative
status of rat [26]. Thus the biological properties of this 800-
year-old decoction, as demonstrated in our previous studies
and here, have been revealed in both cell culture and animal
studies.
The author of DBT Li Dongyuan wrote down the
formulationand the preparationmethods probablybasedon
accumulated experience in clinical application. As proposed
by the author, the stimulation of “Qi”a n d“ Blood”a r et h e
two critical eﬀects of DBT to keep our body in a healthy
balanced state. However, how this herbal decoction could
be explained by modern science is not determined. We oﬀer
two hypotheses to explain the unique biological function of
DBT. First, DBT might contain additional chemicals than
those in the extracts of RA or RAS alone. Very likely, these
additional chemicals are soluble only in DBT, that is, the
boiling of RA and RAS together enhances the solubility of
the chemicals. The additional chemicals couldbe responsible
for the distinct DBT-speciﬁc eﬀects. Unfortunately, the
chemical ﬁngerprint of DBT in our detection method (as
in Figure 1) does not show any additional chemicals as
compared to that of RA and RAS. Thus, the additional
chemicals, if any, could be those that are not detected by
HPLC, for example, polysaccharide. The optimized ratio of
the two herbs in yielding more active ingredients can be
another good explanation for the DBT-speciﬁc eﬀects. Our
chemicalanalysesshowedthathigheramountsofRA-derived
astragaloside IV, calycosin, formononetin, and RAS-derived
ferulic acid were found in the DBT decoction [8]. Second,
there could be a synergistic eﬀect of diﬀerent components
in DBT; this synergistic eﬀect is not present in the extracts
of the single herbs. Unfortunately, we do not have direct
evidencetotestthesehypothesesfromourDBTexperiments.
However, because of the failure of the RA + RAS mixture
to perform the same functions as DBT, we believe that the
second hypothesis is less likely.
ByusingculturedMG-63osteoblasts,thegeneexpression
proﬁling, after the DBT treatment, was revealed. Such DBT-
regulated gene transcription was further validated in the
primary culture of rat osteoblasts. The genomic analysis can
reveal not only the activation eﬀect of DBT in stimulating
the proliferation and the diﬀerentiation in osteoblasts but
also asetofbiologicalresponsive markersthatare speciﬁcally
triggered by DBT. The speciﬁc biomarkers could help to
resolve the action mechanism of DBT. For instance, galectin-
9, a β-galactoside-binding protein, expresses in various
tissues that has implication in modulating cell-cell and cell-
matrix interaction [27]. In addition, the role of galectin-
9 in bone development was revealed to induce osteoblast
proliferation through the c-Src/Erk signaling pathway [28].
CCL-2, CCL-7, and CCL-8 also called monocyte chemo-
tactic protein 1 (MCP-1), MCP-3, and MCP-2, respectively,
are speciﬁcally activated in osteoblast by DBT: they are
important chemokines that belong to the CC chemokine
super-family and play a critical role in the recruitment and
activation ofleukocytes[29, 30].Because leukocytesproduce
factors capable of modulating the activities of osteoclast
and osteoblast; their recruitment is representing a signiﬁcant
event in regulating osseous metabolism.
The regulatory eﬀects of estrogen in MG-63 osteoblast-
like cells were demonstrated previously [31]. By using
anti-sense method, estrogen was shown to increase the
expressions of collagen and alkaline phosphatase via an ERβ.
In line to the anti-sense study, the matrix secretion and
cell proliferation of cultured bone cells were abolished in
the absence of ERβ.I na d d i t i o n ,E R α is also proposed to
have a role in bone development since both ERα and ERβ
are expressed in MG-63 cells, and ERα has been shown to
play a vital role in mediating the osteogenic activities [32].
Therefore, these diﬀerentlines of evidencefurther supported
the close relationship between estrogen and MG-63 cell
proliferation. However, the estrogenic eﬀect in MG-63 cells
is very diﬀerent to that of DBT. These diﬀerences include a
distinctgeneproﬁlingingenechipanalysesbetweenestrogen
and DBT and the insigniﬁcant changes of galectin-8, CCL-
2, CCL-7, and CCL-8 after estrogen application in MG-63
cell cultures (data not shown). Although the ER blocker ICI
182 780 shows partial blockage of DBT-induced osteogenic
eﬀects, this result still supports the estrogenic role of DBT,
because the dose ofICI 182 780 used is expected to have only
∼20% inhibition on the possible ER binding. Moreover, our
preliminary studies by using inhibitors for MAP kinase sug-
gest that the DBT-induced gene activations could be medi-
ated by diﬀerent signaling mechanisms. This observation is
inaccordancewiththe possibilitiesofhaving multi-targetsof
the pharmacological properties of Chinese herbal decoction.12 Evidence-Based Complementary and Alternative Medicine
It is well known that steroid hormones, especially
estrogen, can induce the cell proliferation and subsequently
leads to an increase risk of developing breast cancer. Indeed,
this issue is a major concernof estrogen replacement therapy
for the menopausal women. In contrast, DBT could be
developed as alternative medicines for the patients. The
reasons for this notion include: (i) DBT has been used
over 800 years in China, which has been proven to be safe
for human; (ii) DBT does not alter the proliferation of
the breast cancer cells, even at higher concentration [8, 9];
(iii) DBT improves biochemical and physiological responses,
both in vitro [9, 22]a n din vivo [26, 33, 34] that are related
to menopausal women. In developing DBT as drug for
menopausal women, here we provide the essential elements
in searching the chemical and biological markers for this
decoction, that is, to have a well-controlled herbal decoction
for drug development.
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